{'fraction_non_alphanumeric': 0.019933554817275746, 'fraction_numerical': 0.0, 'mean_word_length': 6.349593495934959, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Benzodiazepines attenuate the pituitary‐adrenal responses to corticotrophin‐releasing hormone in healthy volunteers, but not in patients with Cushing's syndrome

OBJECTIVE The corticotrophin‐releasing hormone (CRH) stimulation test has become established as a powerful tool in differentiating the source of ACTH In patients with Cushing's syndrome. Psychiatric symptoms are common In patients with Cushing's syndrome, and many patients with psychiatric illnesses may show disturbances of function of the pituitary‐adrenal axis; both of these groups of patients may be receiving benzodiazepine drugs when presenting for evaluation of their possible endocrine problems. Both animal and human studies suggest that Interactions occur between benzodiazepines and the hypothalamopituitary‐adrenal axis. We have therefore evaluated the effects of a benzodiazepine drug on the pituitary‐adrenal response to CRH.